EUVIMEDEUVIMED entdecken
Crossref

FLT3 inhibitors and hematopoietic cell transplantation prolong survival in patients with FLT3-ITD-positive AML

Toshihiro Matsukawa, Masahiro Onozawa, Takeshi Kondo, Minoru Kanaya, Daisuke Hidaka, Shuichi Ota, Akio Mori, Akio Shigematsu, Takuto Miyagishima, Yasutaka Kakinoki, Junichi Hashiguchi, Satoshi Yamamoto und 18 weitere

Annals of Hematology · 2024

DOI: 10.1007/s00277-024-06125-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Hematology, 2024. Verfasst von Toshihiro Matsukawa und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan. toshimatsukawa@med.hokudai.ac.jp. Hauptthemen laut MEDLINE: fms-Like Tyrosine Kinase 3, Leukemia, Myeloid, Acute, Hematopoietic Stem Cell Transplantation, Protein Kinase Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myeloid leukemia (AML) is an aggressive hematological malignancy with genetic alterations. The FMS-like tyrosine kinase 3 (FLT3) gene is frequently mutated in adult de novo AML, with two types of mutations: internal tandem duplication (ITD) and point mutations in the tyrosine kinase domain. This study aimed to investigate the impact of FLT3 inhibitors and hematopoietic cell transplantation (HCT) on survival outcomes in patients with FLT3-ITD AML in a real-world setting. We retrospectively analyzed 139 patients with FLT3-ITD-positive AML between 2012 and 2021. The median age was 63 years. In the propensity score-matched cohort, FLT3 inhibitors improved overall survival (OS) compared with patients treated without FLT3 inhibitors (3-year OS: 33.7% vs. 25.8%, p = 0.021). Patients who underwent HCT had superior outcomes to those without HCT (3-year OS: 45.3% vs. 2.2%, p < 0.0001). The combination of FLT3 inhibitors and HCT resulted in the highest OS and relapse-free survival (RFS) rates (3-year OS: 62.4%; 3-year RFS: 44.4%). Disease status before transplantation did not predict the prognosis, but use of FLT3 inhibitors increased survival in patients without complete remission before HCT. These results demonstrate the clinical impact of FLT3 inhibitors on survival outcomes in patients with FLT3-ITD-positive AML, particularly when combined with HCT. FLT3 inhibitors can improve the prognosis of AML with FLT3 mutations, especially in patients who undergo HCT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

fms-Like Tyrosine Kinase 3Leukemia, Myeloid, AcuteHematopoietic Stem Cell TransplantationProtein Kinase InhibitorsHumansMiddle AgedFemaleMaleAgedRetrospective StudiesAdultSurvival RateDisease-Free SurvivalTandem Repeat Sequences

Stichwörter der Autor:innen

FLT3-ITDAcute myeloid leukemiaFLT3 inhibitorHematopoietic cell transplantation

Substanzen

fms-Like Tyrosine Kinase 3FLT3 protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan. toshimatsukawa@med.hokudai.ac.jp.
  • Department of Hematology, Faculty of Medicine, Graduate School of Medicine, Hokkaido University, Kita 15, Nishi 7, Kita-ku, Sapporo, 0608638, Japan. toshimatsukawa@med.hokudai.ac.jp.
  • Department of Hematology, Hokkaido University Faculty of Medicine, Sapporo, Japan.
  • Blood Disorders Center, Aiiku Hospital, Sapporo, Japan.
  • Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan.
  • Department of Hematology, Kushiro Rosai Hospital, Kushiro, Japan.

Zitieren

APA

Matsukawa, T., Onozawa, M., Kondo, T., Kanaya, M., Hidaka, D., Ota, S., Mori, A., Shigematsu, A., Miyagishima, T., Kakinoki, Y., Hashiguchi, J., Yamamoto, S., Yamamoto, M., Wakasa, K., Takahata, M., Ishihara, T., Haseyama, Y., Fujimi, A., Igarashi, T., …, & Teshima, T. (2024). FLT3 inhibitors and hematopoietic cell transplantation prolong survival in patients with FLT3-ITD-positive AML. Annals of Hematology. https://doi.org/10.1007/s00277-024-06125-9

Vancouver

Matsukawa T, Onozawa M, Kondo T, Kanaya M, Hidaka D, Ota S, et al. FLT3 inhibitors and hematopoietic cell transplantation prolong survival in patients with FLT3-ITD-positive AML. Annals of Hematology. 2024. doi:10.1007/s00277-024-06125-9

BibTeX
@article{Matsukawa2024,
  author = {Matsukawa, Toshihiro and Onozawa, Masahiro and Kondo, Takeshi and Kanaya, Minoru and Hidaka, Daisuke and Ota, Shuichi and Mori, Akio and Shigematsu, Akio and Miyagishima, Takuto and Kakinoki, Yasutaka and Hashiguchi, Junichi and Yamamoto, Satoshi and Yamamoto, Masayo and Wakasa, Kentaro and Takahata, Mutsumi and Ishihara, Toshimichi and Haseyama, Yoshihito and Fujimi, Akihito and Igarashi, Tetsuya and Sarashina, Takehiro and Iyama, Satoshi and Kobayashi, Ryoji and Sakai, Hajime and Fujimoto, Katsuya and Inamura, Junki and Kanisawa, Yuji and Hirabayashi, Shinsuke and Endo, Tomoyuki and Hashimoto, Daigo and Teshima, Takanori},
  title = {FLT3 inhibitors and hematopoietic cell transplantation prolong survival in patients with FLT3-ITD-positive AML},
  journal = {Annals of Hematology},
  year = {2024},
  doi = {10.1007/s00277-024-06125-9}
}
Kostenlos starten →